Inactivated enterovirus 71 vaccine produced by 200-L scale serum-free microcarrier bioreactor system provides cross-protective efficacy in human SCARB2 transgenic mouse

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Wu, Chia Ying ^a   Lin, Yi Wen ^b   Kuo, Chia Ho ^a   Liu, Wan Hsin ^a   Tai, Hsiu Fen ^a   Pan, Chien Hung ^a   Chen, Yung Tsung ^a   Hsiao, Pei Wen ^c   Chan, Chi Hsien ^a   Chang, Ching Chuan ^a   Liu, Chung Cheng ^a,d   Chow, Yen Hung ^b,e   Chen, Juine Ruey ^a  

^a Adimmune Corporation   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^d Enimmune Corporation   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM PHOSPHATE; ENTEROVIRUS 71 VACCINE; INACTIVATED VIRUS VACCINE; SQUALENE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; CHEMOKINE; CYTOKINE; INACTIVATED VACCINE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; SCARB2 PROTEIN, HUMAN; SCAVENGER RECEPTOR; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOREACTOR; CROSS PROTECTION; CULTURE MEDIUM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; IMMUNOGENICITY; INFLAMMATION; MICROCARRIER CULTURE; MOUSE; MUSCLE INJURY; NONHUMAN; PARALYSIS; TRANSGENIC MOUSE; VACCINE PRODUCTION; VIRUS PARTICLE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHLOROCEBUS AETHIOPS; COXSACKIEVIRUS INFECTIONS; CROSS REACTION; ENTEROVIRUS A; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; RABBIT; VERO CELL LINE; VIRUS CULTURE;

ANIMALS; BIOREACTORS; CERCOPITHECUS AETHIOPS; CHEMOKINES; COXSACKIEVIRUS INFECTIONS; CROSS REACTIONS; CYTOKINES; ENTEROVIRUS A, HUMAN; GENE EXPRESSION; HUMANS; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; RABBITS; RECEPTORS, SCAVENGER; VACCINES, INACTIVATED; VERO CELLS; VIRAL VACCINES; VIRUS CULTIVATION;

EID: 84942645703     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136420     Document Type: Article

References (46)

1. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999; 341: 929-935. PMID: 10498487
2. Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, Yeh TF, et al. Neurologic complications in children with enterovirus 71 infection. N Engl J Med. 1999; 341: 936-942. PMID: 10498488
3. McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002; 26: 91-107. PMID: 12007645
4. Tee KK, Lam TT, Chan YF, Bible JM, Kamarulzaman A, Tong CY, et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol. 2010; 84: 3339-3350. doi: 10.1128/JVI.01019-09 PMID: 20089660
5. Xu J, Qian Y, Wang S, Serrano JM, Li W, Huang Z, et al. EV71: an emerging infectious disease vaccine target in the Far East? Vaccine 2010; 28: 3516-3521. doi: 10.1016/j.vaccine.2010.03.003 PMID: 20304038
6. Lee MS, Chang LY. Development of enterovirus 71 vaccines. Expert Rev Vaccines 2010; 9: 149-156. doi: 10.1586/erv.09.152 PMID: 20109026
7. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010; 10: 778-790. doi: 10.1016/S1473-3099 (10)70194-8 PMID: 20961813
8. Sabanathan S, Tan le V, Thwaites L, Wills B, Qui PT, Rogier van Doorn H. Enterovirus 71 related severe hand, foot and mouth disease outbreaks in South-East Asia: current situation and ongoing challenges. J Epidemiol Community Health. 2014; 68: 500-502. doi: 10.1136/jech-2014-203836 PMID: 24652348
9. Mao QY, Liao XY, Yu X, Li N, Zhu FC, Zeng Y, et al. Dynamic change of mother-source neutralizing antibodies against enterovirus 71 and coxsackievirus A16 in infants. Chin Med J. 2010; 123: 1679-1684. PMID: 20819628
10. Yan XF, Gao S, Xia JF, Ye R, Yu H, Long JE. Epidemic characteristics of hand, foot, and mouth disease in Shanghai from 2009 to 2010: Enterovirus 71 subgenotype C4 as the primary causative agent and a high incidence of mixed infections with coxsackievirus A16. Scand J Infect Dis. 2012; 44: 297-305. doi: 10.3109/00365548.2011.634433 PMID: 22176514
11. Li L, He Y, Yang H, Zhu J, Xu X, Dong J, et al. Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in Shenzhen, People's Republic of China. J Clin Microbiol. 2005; 43: 3835-3839. PMID: 16081920
12. Mao Q, Wang Y, Yao X, Bian L, Wu X, Xu M, et al. Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum Vaccin Immunother. 2014; 10: 360-367. doi: 10.4161/hv.27087 PMID: 24231751
13. Chong P, Liu CC, Chow YH, Chou AH, Klein M. Review of Enterovirus 71 Vaccines. Clin Infect Dis: an official publication of the Infectious Diseases Society of America. 2014.
14. Yip CC, Lau SK, Woo PC, Yuen KY. Human enterovirus 71 epidemics: what's next? Emerg Health Threats J. 2013; 6: 19780. doi: 10.3402/ehtj.v6i0.19780 PMID: 24119538
15. Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J. 2010; 7: 94. doi: 10.1186/1743-422X-7-94 PMID: 20459851
16. Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, et al. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis. 2014; 14: 308-318. doi: 10.1016/S1473-3099(13) 70342-6 PMID: 24485991
17. Liang ZL, Mao QY, Wang YP, Zhu FC, Li JX, Yao X, et al. Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum Vaccin Immunother. 2013; 9: 1701-1705. doi: 10. 4161/hv.24949 PMID: 23744508
18. Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014; 370: 818-828. doi: 10.1056/NEJMoa1304923 PMID: 24571754
19. Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet 2013; 381: 2024-2032. doi: 10.1016/S0140-6736(13) 61049-1 PMID: 23726161
20. Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014; 370: 829-837. doi: 10.1056/NEJMoa1303224 PMID: 24571755
21. Chou AH, Liu CC, Chang JY, Jiang R, Hsieh YC, Tsao A, et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One 2013; 8: e79783. doi: 10.1371/journal.pone.0079783 PMID: 24278177
22. Li JX, Mao QY, Liang ZL, Ji H, Zhu FC. Development of enterovirus 71 vaccines: from the lab bench to Phase III clinical trials. Expert Rev Vaccines 2014; 13: 609-618. doi: 10.1586/14760584.2014.897617 PMID: 24621093
23. Liu CC, Chow YH, Chong P, Klein M. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases. Vaccine 2014; 32: 6177-6182. doi: 10.1016/j.vaccine. 2014.08.064 PMID: 25218294
24. Cai Y, Liu Q, Huang X, Li D, Ku Z, Zhang Y, et al. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine 2013; 31: 2215-2221. doi: 10.1016/j.vaccine.2013.03.007 PMID: 23499596
25. Cai Y, Ku Z, Liu Q, Leng Q, Huang Z. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. Vaccine 2014; 32: 2406-2412. doi: 10.1016/j.vaccine.2014.03.012 PMID: 24657161
26. Lin CW, Liu CC, Lu TC, Liu SJ, Chow YH, Chong P, et al. Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems. BioMed research international 2014: 670506. doi: 10.1155/2014/670506 PMID: 25006583
27. Chong P, Guo MS, Lin FH, Hsiao KN, Weng SY, Chou AH, et al. Immunological and biochemical characterization of coxsackie virus A16 viral particles. PLoS One 2012; 7: e49973. doi: 10.1371/journal. pone.0049973 PMID: 23226233
28. Chong P, Hsieh SY, Liu CC, Chou AH, Chang JY, Wu SC, et al. Production of EV71 vaccine candidates. Hum Vaccin Immunother. 2012; 8: 1775-1783. doi: 10.4161/hv.21739 PMID: 22992566
29. Chou AH, Liu CC, Chang CP, Guo MS, Hsieh SY, Yang WH, et al. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS One 2012; 7: e34834. doi: 10.1371/journal.pone.0034834 PMID: 22529942
30. Liu CC, Lian WC, Butler M, Wu SC. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine 2007; 25: 19-24. PMID: 16919374
31. Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, Chou AH, et al. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS One 2011; 6: e20005. doi: 10.1371/journal.pone.0020005 PMID: 21603631
32. Butler M, Burgener A, Patrick M, Berry M, Moffatt D, Huzel N, et al. Application of a serum-free medium for the growth of Vero cells and the production of reovirus. Biotechnol Prog. 2000; 16: 854-858. PMID: 11027181
33. Wu SC, Liu CC, Lian WC. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine 2004; 22: 3858-3864. PMID: 15364432
34. Zhang Y, Tan X, Cui A, Mao N, Xu S, Zhu Z, et al. Complete genome analysis of the C4 subgenotype strains of enterovirus 71: predominant recombination C4 viruses persistently circulating in China for 14 years. PLoS One 2013; 8: e56341. doi: 10.1371/journal.pone.0056341 PMID: 23441179
35. Mao Q, Cheng T, Zhu F, Li J, Wang Y, Li Y, et al. The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children. PLoS One 2013; 8: e79599. doi: 10. 1371/journal.pone.0079599 PMID: 24260259
36. Lin YW, Yu SL, Shao HY, Lin HY, Liu CC, Hsiao KN, et al. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One 2013; 8: e57591. doi: 10.1371/journal.pone. 0057591 PMID: 23451246
37. Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, Yan JJ, et al. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol. 2004; 78: 7916-7924. PMID: 15254164
38. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS, et al. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001; 20: 895-904. PMID: 11738755
39. Khong WX, Yan B, Yeo H, Tan EL, Lee JJ, Ng JK, et al. A non mouse-adapted Enterovirus 71 (EV71) strain exhibits neurotropism causing neurological manifestations in a novel mouse model of EV71 infection. J Virol. 2012.
40. Chang JY, Chang CP, Tsai HH, Lee CD, Lian WC, Ih Jen Su, et al. Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. Vaccine 2012; 30: 703-711. doi: 10.1016/j. vaccine.2011.11.087 PMID: 22142585
41. Reed J, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938; 27: 493-497.
42. Matrosovich M, Matrosovich T, Garten W, Klenk HD. New low-viscosity overlay medium for viral plaque assays. Virol J. 2006; 3: 63. PMID: 16945126
43. Weng KF, Chen LL, Huang PN, Shih SR. Neural pathogenesis of enterovirus 71 infection. Microbes Infect. 2010; 12: 505-510. doi: 10.1016/j.micinf.2010.03.006 PMID: 20348010
44. Wang SM, Lei HY, Huang KJ, Wu JM, Wang JR, Yu CK, et al. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis. 2003; 188: 564-570. PMID: 12898444
45. Lin TY, Hsia SH, Huang YC, Wu CT, Chang LY. Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin Infect Dis: an official publication of the Infectious Diseases Society of America 2003; 36: 269-274.
46. Liu CC, Hwang CS, Yang WS, Tsai DC, Wu SH, Chou AH, et al. Long-term immunogenicity studies of formalin-inactivated enterovirus 71 whole-virion vaccine in macaques. PLoS One 2014; 9: e106756. doi: 10.1371/journal.pone.0106756 PMID: 25197967